natgillin/translations-raw huggingface dataset:
IVEMEND is given as a 15-minute infusion 30 minutes before the start of chemotherapy on the first day of chemotherapy.
Zdravilo IVEMEND se daje na prvi dan kemoterapije v obliki 15- minutne infuzije 30 minut pred začetkom kemoterapije.
It must always be given with other medicines that also prevent nausea and vomiting, including a corticosteroid and a 5HT3 antagonist (another type of medicine which prevents nausea and vomiting, such as ondansetron).
Zdravilo se vedno daje skupaj z drugimi zdravili, ki prav tako preprečujejo slabost in bruhanje, vključno s kortikosteroidom in antagonistom 5- HT3 (drugo vrsto zdravil, ki preprečujejo slabost in bruhanje, kot je denimo ondansetron).
The patient should continue receiving treatment by mouth for a further two to three days.
Bolnik mora še dva do tri dni nadaljevati s peroralnim zdravljenjem.
How does IVEMEND work?
Kako zdravilo IVEMEND deluje?
The active substance in IVEMEND, fosaprepitant, is a ‘ prodrug ’ of aprepitant.
Zdravilna učinkovina v zdravilu IVEMEND, fosaprepitant, je „ predzdravilo “ aprepitanta.
This means that it is converted to aprepitant in the body.
To pomeni, da se v telesu pretvori v aprepitant.
By blocking the receptors, IVEMEND can prevent nausea and vomiting, which often happens during and after chemotherapy.
Zdravilo IVEMEND lahko z blokiranjem receptorjev prepreči slabost in bruhanje, ki se pogosto pojavita med kemoterapijo in po njej.
Medicines containing aprepitant have been available in the European Union as EMEND since 2003.
Zdravila, ki vsebujejo aprepitant, so v Evropski uniji na voljo od leta 2003 pod imenom EMEND.
How has IVEMEND been studied?
Kako je bilo zdravilo IVEMEND raziskano?
The effects of IVEMEND were first tested in experimental models before being studied in humans.
Učinki zdravila IVEMEND so bili najprej preizkušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
The company presented data to show that an infusion of 115 mg IVEMEND produces the same amount of aprepitant in the body as one EMEND 125 mg capsule.
Družba je predstavila podatke, ki kažejo, da se z infundiranjem 115 mg zdravila IVEMEND v telesu tvori enaka količina aprepitanta kot ob zaužitju 125 mg kapsule zdravila EMEND.
There were two studies in highly emetogenic chemotherapy, involving a total of 1,094 patients, where EMEND combined with dexamethasone (a 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Družba je v podporo uporabi zdravila IVEMEND predložila tudi podatke, ki zagovarjajo uporabo zdravila EMEND, saj so v vseh študijah zdravila EMEND bolniki prejeli 125 mg kapsulo zdravila na dan 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged corticosteroid) and ondansetron was compared with a standard treatment of only dexamethasone and ondansetron.
Opravljeni sta bili tudi dve študiji zelo emetogene kemoterapije, v katerih je sodelovalo skupno 1. 094 bolnikov.
One study in less emetogenic chemotherapy compared EMEND in the same way in 866 patients with breast cancer who were receiving cyclophosphamide with or without doxorubicin or epirubicin.
V eni študiji manj emetogene kemoterapije so zdravilo EMEND primerjali na enak način, in sicer pri 866 bolnikih z rakom na prsih, ki so prejemali ciklofosfamid z ali brez doksorubicina ali epirubicina.
The measure of effectiveness was the proportion of patients who had nausea and vomiting over the five days after receiving the chemotherapy.
Merilo učinkovitosti je bil delež bolnikov, pri katerih sta se v petih dneh po opravljeni kemoterapiji pojavila slabost in bruhanje.
What benefit has IVEMEND shown during the studies?
Kakšne koristi je zdravilo IVEMEND izkazalo med raziskavami?
In the studies in highly emetogenic chemotherapy, the proportion of patients who had no nausea or vomiting over five days was 67.7% in the EMEND group and 47.8% in the comparator group.
V študijah zelo emetogene kemoterapije je bil delež bolnikov, pri katerih se v petih dneh nista pojavila slabost ali bruhanje, v skupini, ki je prejemala zdravilo EMEND, 67, 7%, v primerjalni skupini pa 47, 8%.
In the study in patients receiving less emetogenic chemotherapy, the percentages were 50.8% (EMEND group) and 42.5% (comparator group).
V študiji pri bolnikih, ki so bili zdravljeni z manj emetogeno kemoterapijo, so ti deleži znašali 50, 8% (skupina, ki je prejemala zdravilo EMEND) in 42, 5% (primerjalna skupina).
This benefit shown by EMEND 125 mg capsules given on the first day of chemotherapy can be applied to IVEMEND as the two medicines were shown to produce equivalent levels of aprepitant in the body.
Koristi, ki so jih pokazale 125 mg kapsule zdravila EMEND, zaužite na prvi dan kemoterapije, se lahko pričakujejo tudi pri zdravilu IVEMEND, saj je bilo dokazano, da obe zdravili tvorita enako količino aprepitanta v telesu.
What is the risk associated with IVEMEND?
Kakšna tveganja so povezana z zdravilom IVEMEND?
The most common side effects with IVEMEND (seen in between 1 and 10 patients in 100) are increased liver enzymes, headache, dizziness, hiccups, constipation, diarrhoea, dyspepsia (indigestion), eructation (burping), anorexia (loss of appetite) and asthenia or fatigue (weakness or tiredness). For the full list of all side effects reported with IVEMEND, see the Package Leaflet.
Za celoten seznam neželenih učinkov, opaženih pri uporabi zdravila IVEMEND, glejte Navodilo za uporabo.
IVEMEND should not be used in people who may be hypersensitive (allergic) to aprepitant, to polysorbate 80 or any of the other ingredients.
Zdravila IVEMEND se ne sme uporabljati pri osebah, ki utegnejo biti preobčutljive za (alergične na) aprepritant, polisorbat 80 ali katerokoli drugo sestavino zdravila.
IVEMEND cannot be given at the same time as the following medicines: • pimozide (used to treat mental illness), • astemizole, terfenadine (commonly used to treat allergy symptoms - these medicines may be available without prescription), • cisapride (used to relieve certain stomach problems).
Zdravila IVEMEND se ne sme uporabljati sočasno z naslednjimi zdravili: • pimozid (uporablja se za zdravljenje duševnih bolezni), • astemizol, terfenadin (ki se navadno uporabljata za zdravljenje simptomov alergije – ti zdravili sta morda na voljo brez recepta), • cisaprid (zdravilo za blaženje določenih težav z želodcem).
Why has IVEMEND been approved?
Zakaj je bilo zdravilo IVEMEND odobreno?
The Committee for Medicinal products for Human Use (CHMP) decided that IVEMEND is effective in the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Odbor za zdravila za uporabo v humani medicini (CHMP) je sklenil, da je zdravilo IVEMEND učinkovito pri preprečevanju akutne in zapoznele navzeje in bruhanja, povezanih z zelo emetogeno kemoterapijo raka s cisplatinom, ter navzeje in bruhanja, povezanih z zmerno emetogeno kemoterapijo raka.
The Committee decided that IVEMEND’ s benefits are greater than its risks and recommended that IVEMEND be given marketing authorisation.
Odbor je odločil, da so koristi zdravila IVEMEND večje od z njim povezanih tveganj, zato je za zdravilo IVEMEND priporočil odobritev dovoljenja za promet.
Other information about IVEMEND:
Druge informacije o zdravilu IVEMEND:
The European Commission granted a marketing authorisation valid throughout the European Union for IVEMEND to Merck Sharp & Dohme Ltd on 11 January 2008.
Evropska komisija je dovoljenje za promet z zdravilom IVEMEND, veljavno po vsej Evropski uniji, odobrila družbi Merck Sharp & Dohme Ltd dne 11. januarja 2008.
The full EPAR for IVEMEND can be found here.
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo IVEMEND je na voljo tukaj.
IVEMEND 115 mg powder for solution for infusion.
IVEMEND 115 mg prašek za raztopino za infundiranje
Each vial contains fosaprepitant dimeglumine equivalent to 115 mg fosaprepitant.
Ena viala vsebuje dimegluminijev fosaprepitant, ki ustreza 115 mg fosaprepitanta.
After reconstitution and dilution 1 ml of solution contains 1 mg fosaprepitant (see section 6.6).
Po pripravi in redčenju 1 ml raztopine vsebuje 1 mg fosaprepitanta (glejte poglavje 6. 6).
White to off-white amorphous powder.
prašek za raztopino za infundiranje bel do sivobel amorfni prašek
Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy.
Preprečevanje akutne in zapoznele navzee in bruhanja, povezanih z zelo emetogeno kemoterapijo rakavih bolezni na osnovi cisplatina.
Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Preprečevanje navzee in bruhanja, povezanih z zmerno emetogeno kemoterapijo rakavih bolezni.
IVEMEND is given as part of a combination therapy (see section 4.2).
Zdravilo IVEMEND je namenjeno za uporabo v sklopu kombiniranega zdravljenja (glejte poglavje 4. 2).
IVEMEND is a lyophilized prodrug of aprepitant containing polysorbate 80 (PS80) for intravenous administration.
Zdravilo IVEMEND je liofilizirano predzdravilo aprepitanta, ki vsebuje polisorbat 80 (PS80), za intravensko uporabo.
Aprepitant is available as capsules for oral administration.
Aprepitant je na voljo v obliki kapsul za peroralno uporabo.
Posology IVEMEND (115 mg) may be substituted for aprepitant (125 mg) prior to chemotherapy, on Day 1 only of the chemotherapy induced nausea and vomiting (CINV) regimen as an infusion administered over 15 minutes (see section 6.6).
Odmerjanje Zdravilo IVEMEND (115 mg) v obliki 15- minutne infuzije lahko prvi dan pred kemoterapijo za preprečevanje s kemoterapijo povzročene navzee in bruhanja (CINV; “ chemotherapy induced nausea and vomiting ”) nadomesti uporabo aprepitanta (125 mg) (glejte poglavje 6. 6).
The 3-day CINV regimen includes IVEMEND (115 mg) 30 minutes prior to chemotherapy treatment or aprepitant (125 mg) one hour prior to chemotherapy treatment on Day 1; aprepitant (80 mg) on Days 2 and 3; in addition to a corticosteroid and a 5-HT3 antagonist.
Tridnevni režim preprečevanja CINV vključuje: prvi dan zdravilo IVEMEND (115 mg) 30 minut pred začetkom kemoterapije ali aprepitant (125 mg) eno uro pred začetkom kemoterapije, drugi in tretji dan aprepitant (80 mg) ter kortikosteroid in antagonist 5- HT3.
2 The following regimen is recommended, based on clinical studies with aprepitant, for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy.
2 Na osnovi kliničnih študij z aprepitantom za preprečevanje navzee in bruhanja zaradi emetogene kemoterapije rakavih bolezni priporočamo naslednji režim zdravljenja.
IVEMEND
IVEMEND aprepitant
none
intravensko brez
none
80 mg
none
brez peroralno 80 mg
none
brez peroralno
none
brez brez
8 mg orally 8 mg orally
8 mg peroralno 8 mg peroralno
Ondansetron
ondansetron
32 mg intravenously
32 mg intravensko
none none
brez brez
Ondansetron was administered intravenously 30 minutes prior to chemotherapy treatment on Day 1.
V kliničnih študijah so bolniki: aprepitant prejeli peroralno, prvi dan 1 uro pred kemoterapijo, drugi in tretji dan pa zjutraj. deksametazon prejeli prvi dan 30 minut pred kemoterapijo, od drugega do četrtega dne pa zjutraj.
Aprepitant
aprepitant
2 x 8 mg orally
2 x 8 mg peroralno
Dexamethasone was administered 30 minutes prior to chemotherapy treatment on Day 1.
V kliničnih študijah so bolniki: aprepitant prejeli peroralno, prvi dan 1 uro pred kemoterapijo, drugi in tretji dan pa zjutraj. deksametazon prejeli prvi dan 30 minut pred kemoterapijo.
One 8 mg capsule of ondansetron was administered 30 to 60 minutes prior to chemotherapy treatment and one 8 mg capsule was administered 8 hours after first dose on Day 1.
Odmerek deksametazona je bil določen upoštevajoč medsebojno delovanje zdravil. eno 8 mg kapsulo ondansetrona prejeli prvi dan od 30 do 60 minut pred kemoterapijo in eno 8 mg kapsulo 8 ur po prvem odmerku.
Efficacy data on combination with other corticosteroids and 5-HT3 antagonists are limited.
Podatki o učinkovitosti pri sočasni uporabi z drugimi kortikosteroidi in antagonisti 5- HT3 so omejeni.
For additional information on the co-administration with corticosteroids, see section 4.5.
Za dodatne podatke o sočasni uporabi kortikosteroidov glejte poglavje 4. 5.
Refer to the full product information of co-administered antiemetic agents.
Vse sočasno uporabljene antiemetike morate uporabljati v skladu z njihovimi navodili za uporabo.
Elderly No dose adjustment is necessary for the elderly.
Starejši bolniki Pri starejših bolnikih odmerka ni treba prilagajati.
Renal Impairment No dose adjustment is necessary for patients with renal insufficiency or for patients with end stage renal disease undergoing haemodialysis (see section 5.2).
Okvara ledvic Pri bolnikih z ledvično insuficienco in bolnikih z odpovedjo ledvic v končnem stadiju, ki se zdravijo s hemodializo, odmerka ni treba prilagajati (glejte poglavje 5. 2).
Hepatic Impairment No dose adjustment is necessary for patients with mild hepatic insufficiency.
Okvara jeter Pri bolnikih z blago insuficienco jeter odmerka ni treba prilagajati.
There are limited data in patients with moderate hepatic insufficiency and no data in patients with severe hepatic insufficiency (see sections 4.4 and 5.2).
Pri bolnikih z zmerno insuficienco jeter so podatki pomanjkljivi, pri bolnikih s hudo insuficienco jeter pa podatki niso na voljo (glejte poglavji 4. 4 in 5. 2).
Children and adolescents IVEMEND is not recommended for use in children below the age of 18 years of age due to insufficient data on safety and efficacy (see section 5.2).
Otroci in mladostniki Zaradi nezadostnih podatkov o varnosti in učinkovitosti uporabe zdravila IVEMEND pri otrocih, mlajših od 18 let, ne priporočamo (glejte poglavje 5. 2).
3 IVEMEND should be administered intravenously and should not be given by the intramuscular or subcutaneous route.
Ne sme se ga dajati intramuskularno ali subkutano.
Intravenous administration occurs preferably through a running intravenous infusion over 15 minutes (see section 6.6).
Po možnosti je treba zdravilo aplicirati v obliki 15- minutne intravenske infuzije (glejte poglavje 6. 6).
Hypersensitivity to the active substance, aprepitant, or to polysorbate 80 or any of the other excipients.
Preobčutljivost za zdravilno učinkovino, aprepitant, polisorbat 80 ali katerokoli pomožno snov.
Co-administration with pimozide, terfenadine, astemizole or cisapride (see section 4.5).
Sočasna uporaba pimozida, terfenadina, astemizola ali cisaprida (glejte poglavje 4. 5).
There are limited data in patients with moderate hepatic insufficiency and no data in patients with severe hepatic insufficiency.
Pri bolnikih z zmerno insuficienco jeter so podatki o uporabi zdravila pomanjkljivi, pri bolnikih s hudo insuficienco jeter pa podatki o uporabi zdravila niso na voljo.
IVEMEND should be used with caution in these patients (see section 5.2).
Pri teh bolnikih je treba zdravilo IVEMEND uporabljati previdno (glejte poglavje 5. 2).
IVEMEND and oral aprepitant should be used with caution in patients receiving concomitant orally administered medicinal products that are metabolised primarily through CYP3A4 (see section 4.5).
Pri bolnikih, ki sočasno jemljejo peroralna zdravila, ki se primarno presnavljajo s CYP3A4, je treba zdravilo IVEMEND in peroralni aprepitant uporabljati previdno (glejte poglavje 4. 5).
Additionally, concomitant administration with irinotecan should be approached with particular caution as the combination might result in increased toxicity.
Previdnost je še posebej potrebna pri sočasni uporabi irinotekana, saj se lahko pri sočasni uporabi poveča toksični učinek.
Co-administration of fosaprepitant with ergot alkaloid derivatives, which are CYP3A4 substrates, may result in elevated plasma concentrations of these medicinal products.
Pri sočasni uporabi fosaprepitanta in alkaloidov rženega rožička (ergot alkaloidi), ki so substrat za CYP3A4, se lahko zvišajo plazemske koncentracije teh zdravil.
Therefore, caution is advised due to the potential risk of ergot-related toxicity.
Zaradi možnega tveganja za pojav toksičnih učinkov ergot alkaloidov je potrebna previdnost.
Co-administration of oral aprepitant with warfarin results in decreased prothrombin time, reported as International Normalised Ratio (INR).
Pri sočasni uporabi peroralnega aprepitanta in varfarina se je zmanjšal protrombinski čas, izražen z internacionalnim normaliziranim razmerjem (INR).
In patients on chronic warfarin therapy, the INR should be monitored closely during treatment with oral aprepitant and for 2 weeks following each 3-day regimen of fosaprepitant followed by oral aprepitant for chemotherapy induced nausea and vomiting (see section 4.5).
Pri bolnikih, ki so na kroničnem zdravljenu z varfarinom, je treba med zdravljenjem s peroralnim aprepitantom in še 2 tedna po vsakem 3- dnevnem ciklusu zdravljenja navzee in bruhanja zaradi kemoterapije s fosaprepitantom, ki mu sledi zdravljenje s peroralnim aprepitantom, vrednosti INR skrbno nadzorovati (glejte poglavje 4. 5).
The efficacy of hormonal contraceptives may be reduced during and for 28 days after administration of aprepitant.
Med zdravljenjem z aprepitantom in še 28 dni po koncu zdravljenja z aprepitantom je lahko učinkovitost hormonskih kontraceptivov manjša.
Alternative or back-up methods of contraception should be used during treatment with fosaprepitant or aprepitant and for 2 months following the last dose of aprepitant (see section 4.5).
Med zdravljenjem s fosaprepitantom ali aprepitantom in še 2 meseca po zadnjem odmerku aprepitanta mora bolnica uporabljati drugo ali dodatno kontracepcijsko metodo (glejte poglavje 4. 5).
Concomitant administration of fosaprepitant with medicinal products that strongly induce CYP3A4 activity (e. g. rifampicin, phenytoin, carbamazepine, phenobarbital) should be avoided as the combination results in reductions of the plasma concentrations of aprepitant (see section 4.5).
Sočasni uporabi fosaprepitanta in zdravil, ki močno inducirajo aktivnost CYP3A4 (npr. rifampicin, fenitoin, karbamazepin, fenobarbital), se je treba izogibati, saj se pri sočasni uporabi zmanjšajo plazemske koncentracije aprepitanta (glejte poglavje 4. 5).
John’ s Wort is not recommended.
Sočasne uporabe fosaprepitanta in šentjanževke ne priporočamo.
Concomitant administration of fosaprepitant with medicinal products that inhibit CYP3A4 activity (e. g. ritonavir, ketoconazole, clarithromycin, telithromycin) should be approached cautiously as the combination results in increased plasma concentrations of aprepitant (see section 4.5).
Pri sočasni uporabi fosaprepitanta in zdravil, ki zavirajo aktivnost CYP3A4 (npr. ritonavir, ketokonazol, klaritromicin, telitromicin) je potrebna previdnost, saj se pri sočasni uporabi zvišajo plazemske koncentracije aprepitanta (glejte poglavje 4. 5).
IVEMEND should not be given as a bolus injection, but should always be diluted and given as a slow intravenous infusion (see section 4.2).
Vedno ga je treba dajati razredčenega v obliki počasne intravenske infuzije (glejte poglavje 4. 2).
IVEMEND should not be administered intramuscularly or subcutaneously.
Zdravila IVEMEND se ne sme dajati intramuskularno ali subkutano.
Mild injection site thrombosis has been observed at higher doses (see section 4.9).
Pri uporabi velikih odmerkov so poročali o pojavu blage tromboze na mestu injiciranja (glejte poglavje 4. 9).
Drug interactions following administration of fosaprepitant are likely to occur with medicinal products that interact with oral aprepitant.
Po intravenski aplikaciji fosaprepitanta se lahko pojavijo interakcije z drugimi zdravili, ki medsebojno delujejo s peroralnim aprepitantom.
The following information was derived from data with oral aprepitant and studies conducted with fosaprepitant and midazolam or diltiazem.
Naslednje informacije so povzete iz podatkov, pridobljenih s peroralnim aprepitantom, in študij, ki so bile izvedene s fosaprepitantom in midazolamom ali diltiazemom.
4 Aprepitant is a substrate, a moderate inhibitor, and an inducer of CYP3A4.
4 Aprepitant je substrat, zmerni zaviralec in induktor CYP3A4.
During treatment with oral aprepitant, CYP3A4 is inhibited.
Med zdravljenjem s peroralnim aprepitantom je aktivnost CYP3A4 zavrta.
After the end of treatment, oral aprepitant causes a transient moderate induction of CYP2C9 and a transient mild induction of CYP3A4 and glucuronidation.
Peroralni aprepitant po koncu zdravljenja povzroči prehodno zmerno indukcijo CYP2C9 in blago prehodno indukcijo CYP3A4 in glukuronidacije.
Effect of aprepitant on the pharmacokinetics of other agents CYP3A4 inhibition As a moderate inhibitor of CYP3A4, aprepitant can increase plasma concentrations of orally co-administered medicinal products that are metabolised through CYP3A4.
Vpliv aprepitanta na farmakokinetiko drugih učinkovin Zaviranje CYP3A4 Kot zmerni zaviralec CYP3A4 lahko aprepitant zviša plazemske koncentracije sočasno uporabljenih peroralnih zdravil, ki se presnavljajo s CYP3A4.
The AUC of orally administered CYP3A4 substrates may increase up to approximately 3-fold during the 3-day treatment with fosaprepitant followed by oral aprepitant; the effect of aprepitant on the plasma concentrations of intravenously administered CYP3A4 substrates is expected to be smaller.
Pričakujemo manjši vpliv aprepitanta na plazemske koncentracije intravensko uporabljenih substratov za CYP3A4.
Caution is advised during concomitant administration of fosaprepitant and CYP3A4 substrates.
Pri sočasni uporabi fosaprepitanta in substratov za CYP3A4 je potrebna previdnost.
Inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of these medicinal products, potentially causing serious or life-threatening reactions.
Aprepitant zavira CYP3A4, zato se lahko zvišajo plazemske koncentracije teh zdravil, kar lahko povzroči pojav resnih ali življenjsko nevarnih reakcij.
Induction As a moderate inducer of CYP2C9 and a mild inducer of CYP3A4 and glucuronidation, aprepitant can decrease plasma concentrations of substrates eliminated by these routes within two weeks following initiation of dosing regimen.
Indukcija Kot zmerni induktor CYP2C9 ter blagi induktor CYP3A4 in glukuronidacije, lahko aprepitant v dveh tednih po začetku zdravljenja zniža plazemske koncentracije substratov, ki se izločajo po teh poteh.
This effect may become apparent only after the end of a 3 day regimen of fosaprepitant followed by aprepitant.
Ta učinek se lahko pokaže le po koncu 3- dnevnega zdravljenja s fosaprepitantom, ki mu sledi zdravljenje s peroralnim aprepitantom.
For CYP2C9 and CYP3A4 substrates, the induction is transient with a maximum effect reached 3-5 days after end of the oral aprepitant 3-day treatment.
Indukcija substratov CYP2C9 in CYP3A4 je prehodna, največji učinek je dosežen v 3- 5 dneh po koncu 3- dnevnega zdravljenja s peroralnim aprepitantom.
The effect is maintained for a few days, thereafter slowly declines and is clinically insignificant by two weeks after end of oral aprepitant treatment.
Učinek traja nekaj dni, potem pa počasi pojema in v dveh tednih po koncu zdravljenja s peroralnim aprepitantom postane klinično nepomemben.
Mild induction of glucuronidation is also seen with 80 mg oral aprepitant given for 7 days.
O blagi indukciji glukuronidacije so poročali tudi pri 7- dnevni uporabi peroralnega aprepitanta v odmerku 80 mg.
Caution is advised when warfarin, acenocoumarol, tolbutamide, phenytoin or other medicinal products that are known to be metabolised by CYP2C9 are administered during this time period.
V tem obdobju svetujemo previdnost pri uporabi varfarina, acenokumarola, tolbutamida, fenitoina in drugih zdravil, ki se presnavljajo s CYP2C9.
Fosaprepitant or aprepitant does not seem to interact with the P-glycoprotein transporter, as demonstrated by the lack of interaction of oral aprepitant with digoxin.
Peroralni aprepitant medsebojno ne deluje z digoksinom, zato fosaprepitant in aprepitant verjetno ne vplivata na P- glikoproteinski prenašalec.